Sign In
Buy DIOD
$116.22
+2.09 (+1.83%)
At Close: Jun 03, 2026
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics
12:30pm, Tuesday, 23'rd Jun 2020
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that for $275 million the company will acquire a 49.9 percent equity interest in Pionyr Immunotherapeutics Inc., a privately held company developin
India's Cipla to price remdesivir version for COVID-19 under $66
11:29am, Tuesday, 23'rd Jun 2020
Indian drugmaker Cipla Ltd will price its generic version of Gilead Sciences Inc's antiviral drug remdesivir for use in COVID-19 patients at less than 5,000 rupees ($66), the company said. Cipla and
Coronavirus Latest: Monday, June 22
07:37pm, Monday, 22'nd Jun 2020
As new cases of coronavirus continue to rise in the United States, Pfizer and Gilead Sciences announce the latest developments in their trials and New York City begins its phase 2 of reopening. Yahoo
NYU Pulmonologist: COVID-19 is ‘a virus not like any other we’ve seen’
06:35pm, Monday, 22'nd Jun 2020
Pulmonologist at NYU Langone Medical Center and Independent Women's Forum Visiting Fellow Dr. Qanta Ahmed joins Yahoo Finance’s Zack Guzman to discuss the rise in coronavirus cases as the White Hous
Gilead Aims To Produce More Than 2 Million Remdesivir Courses By Year-End
05:45pm, Monday, 22'nd Jun 2020
Gilead Sciences Inc. (GILD) said it expects to produce more than 2 million treatment courses of its experimental coronavirus drug candidate remdesivir by the end of the year and many millions more in
Coronavirus update: Trump fans controversy over testing as cases spike worldwide
05:29pm, Monday, 22'nd Jun 2020
Trump sparked a new controversy by suggesting that testing more people for the coronavirus has contributed to the U.S. holding the top spot in the world for COVID-19 diagnoses.
Gilead to Begin Phase 1 Trials of an Inhaled Version of Remdesivir
05:18pm, Monday, 22'nd Jun 2020
Biotech said it will start Phase 1 trials of an inhaled version of remdesivir in August, but the market has been cool to the news for the potential Covid-19 treatment.
What to Do with Gilead Sciences (GILD) Stock Right Now?
02:28pm, Monday, 22'nd Jun 2020
HealthInvest Partners AB is the investment management company of HealthInvest Small & MicroCap Fund. HealthInvest Partners recently released its April month Investor Letter, a copy of which you can do
Gilead's stock falls as it announces clinical trial for inhaled remdesivir
01:34pm, Monday, 22'nd Jun 2020
Shares of Gilead Sciences Inc. were down 1.2% in trading on Monday after the drugmaker said it plans to start Phase 1 clinical trials for an inhaled version of remdesivir, its treatment for severely
Gilead to test inhaled version of remdesivir on COVID-19 patients in August
01:15pm, Monday, 22'nd Jun 2020Indian Drugmakers Get Regulatory Nod For Generic Version Of Gilead’s Remdesivir
07:17am, Monday, 22'nd Jun 2020
India’s drug regulator granted Cipla Ltd. and Hetero Labs the approval to produce and sell a generic version of Gilead Sciences Inc.’s (GILD) coronavirus drug candidate remdesivir.The two Indian d
Are Robust Financials Driving The Recent Rally In Diodes Incorporated's (NASDAQ:DIOD) Stock?
01:31pm, Sunday, 21'st Jun 2020
Diodes (NASDAQ:DIOD) has had a great run on the share market with its stock up by a significant 48% over the last...
India gives Hetero Labs approval to make Gilead's COVID-19 drug
11:26am, Sunday, 21'st Jun 2020
India's drug regulator has given Hetero Labs the green light to manufacture and market its generic version of Gilead Science's experimental COVID-19 treatment remdesivir, the Indian pharmaceutical com
Biotech Stocks Are Getting Ready to Run. How to Play It.
01:48pm, Saturday, 20'th Jun 2020
Given the amount of attention paid to Covid-19 treatments and vaccines, it would be easy to assume that all of the good news was already reflected in biotech stocks. That’s not quite the case.
Parametric Portfolio Associates LLC Has $5.91 Million Stock Holdings in Diodes Incorporated (NASDAQ:DIOD)
05:43am, Saturday, 20'th Jun 2020
Parametric Portfolio Associates LLC lessened its stake in Diodes Incorporated (NASDAQ:DIOD) by 5.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fir
